Anton Pottegård, MScPharm, PhD, clinical pharmacology and pharmacy, department of public health, University of Southern Denmark, Odense, and lead author of study titled “Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma,” published in JAMA Internal Medicine.
There’s new evidence that the drug hydrochlorothiazide (HCTZ) raises risk for melanoma, a deadly skin cancer.
